Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).
Matthew Scott Ernst(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Naveen S. Basappa, J. Connor Wells(Queen's University), Vishal Navani(Hunter Medical Research Institute), Sumanta K. Pal(City of Hope), Ajjai Alva(Michigan Medicine), Toni K. Choueiri(Harvard University), Bernadett Szabados(Queen Mary University of London), Chris Labaki(Beth Israel Deaconess Medical Center), Luís Meza(City of Hope), Frede Donskov(Aarhus University Hospital), Georg A. Bjarnason(Sunnybrook Health Science Centre), D. Scott Ernst, Lori Wood(Dalhousie University), Francis Parnis, Cristina Suárez(Complejo Hospitalario de Salamanca), Takeshi Yuasa(Japanese Foundation For Cancer Research), Rana R. McKay(University of California San Diego), Anil Kapoor(People’s University)
Cited by 3
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k